While the active pharmaceutical ingredient for semaglutide is abundant, the real bottleneck for generic supply is the specialized, regulated "fill and finish" process. This final assembly stage requires years to build capacity, potentially constraining the market's ability to meet surging demand.
Despite the arrival of low-cost generic semaglutide, superior drugs like Tirzepatide, which offers better efficacy and tolerability, can command premium prices. This creates a durable, high-value market segment that coexists with, rather than being eroded by, cheaper alternatives.
The introduction of low-cost generic semaglutide in India revealed massive pent-up demand. Volumes surged sixfold in just two months, driving such significant market expansion that the total market value is projected to grow eightfold by 2030, even with lower per-unit prices.
The introduction of oral GLP-1 medications is proving to be a market expansion strategy, not a cannibalization one. Data shows that the majority of patients starting on oral versions are new to the GLP-1 category entirely, indicating the new form factor overcomes a key barrier to adoption.